The cpt code for mri of breast with and without contrast is 77049 when both breasts are imaged and 77048 when only one breast is imaged. Radiology billers, technologists, and patients all run into these numbers when a claim is filed, an authorization is requested, or an estimate is quoted. Getting the code right matters because a single wrong digit can trigger a denial, a delayed scan, or a surprise bill.
The cpt code for mri of breast with and without contrast is 77049 when both breasts are imaged and 77048 when only one breast is imaged. Radiology billers, technologists, and patients all run into these numbers when a claim is filed, an authorization is requested, or an estimate is quoted. Getting the code right matters because a single wrong digit can trigger a denial, a delayed scan, or a surprise bill.
Breast MRI uses a strong magnetic field, radiofrequency pulses, and an intravenous gadolinium-based contrast agent to create detailed images of breast tissue. Unlike mammography, it does not rely on ionizing radiation, and it can detect cancers that are invisible on mammograms or ultrasound, especially in dense breasts. Because the exam usually includes pre-contrast and post-contrast sequences, the American Medical Association created combined codes that describe the entire study in one line item.
Understanding a breast mri cpt code starts with knowing what CPT actually is. Current Procedural Terminology is a five-character numeric system maintained by the AMA and used by Medicare, Medicaid, and commercial insurers to describe medical services. Each code represents a defined bundle of work. For breast MRI, that bundle includes the scan, the contrast injection technique, image post-processing, and computer-aided detection when it is performed.
Since January 2023, the breast MRI family has contained four codes: 77046 and 77047 for studies without contrast, and 77048 and 77049 for studies without and with contrast. In each pair, the first code is unilateral and the second is bilateral. Before the revision, computer-aided detection was reported separately with a Category III code, but that code was deleted and its work was folded into the primary codes.
Most patients searching this topic fall into one of three groups. The first group is women at high risk for breast cancer, including BRCA1 and BRCA2 carriers, who receive annual screening MRI alongside mammography. The second group is women with a new cancer diagnosis who need staging to measure tumor extent. The third group is patients who need problem solving after an unclear mammogram or ultrasound. All three typically undergo the combined study, so 77049 is the most frequently billed code.
This article walks through each code, the modifiers that accompany it, and the HCPCS codes for the contrast agent. You will also see how diagnosis codes support medical necessity, why Medicare treats screening breast MRI differently from commercial plans, and which billing errors cause the most denials. Technologists preparing for the ARRT MRI registry exam will find the coding context useful too, because protocol questions often connect to why contrast phases are acquired.
Throughout, remember that coding rules change annually and payer policies vary by state and plan. Treat this guide as an educational overview rather than billing advice. Before submitting a claim or scheduling a scan, confirm the current CPT manual language, your payer's medical policy, and any authorization requirements with your imaging center's billing team. A five-minute verification call is far cheaper than appealing a denied claim months later.
Reports MRI of one breast with no contrast agent. It is used when contrast is contraindicated, such as severe kidney impairment, or when the clinical question involves only silicone implant integrity on a single side.
Reports MRI of both breasts without contrast. Implant rupture evaluation is the classic use, because silicone-sensitive sequences show a rupture clearly without any gadolinium injection or added cost.
Reports a pre-contrast and post-contrast study of one breast. Typical examples are staging a known cancer in the remaining breast after mastectomy or following a single-sided finding that needs further characterization.
The answer to the primary question. It covers both breasts, pre-contrast and dynamic post-contrast sequences, post-processing, and computer-aided detection. It is used for high-risk screening, staging, and treatment response monitoring.
A claim for 77049 describes one complete study: pre-contrast sequences, the intravenous contrast injection, dynamic post-contrast series, subtraction or post-processing, and computer-aided detection when it is used. Because all of that work sits inside a single code, billers must not add separate lines for the individual sequences or for the injection itself. Unbundling is one of the quickest ways to trigger a payer audit, even when the intent was simply to document every step.
Choose between 77048 and 77049 by counting the breasts actually imaged, not the breasts a patient has. A woman who has had a mastectomy on one side and undergoes MRI of the remaining breast is reported with the unilateral code, 77048. A woman with both breasts intact who is scanned for high-risk screening gets 77049. Laterality should appear in the order, the technologist worksheet, and the final report so that all three documents agree.
Modifiers refine the code. Use modifier 26 when a radiologist bills only the professional interpretation and modifier TC when a facility bills only the technical component. A freestanding imaging center that owns the scanner and employs the radiologist bills globally, with no modifier. Add LT or RT to the unilateral codes to identify the side. Do not append modifier 50 to 77049 or 77047, because those descriptors already include both breasts.
The contrast agent itself is reported with a HCPCS Level II supply code, not a CPT code. Gadobutrol is reported with A9585 per 0.1 mL, and gadoterate meglumine with A9575 per 0.1 mL. At the standard dose of 0.1 mmol/kg, a 70 kg patient receiving a 1.0 molar agent gets about 7 mL, which translates to 70 billing units. Always report the exact volume administered, following payer rules on documented waste.
Diagnosis codes tell the payer why the scan was necessary. For high-risk screening, imaging centers commonly pair Z12.39 (other special screening examination of the breast) with a risk code such as Z15.01 for genetic susceptibility or Z80.3 for a family history of breast cancer. For staging, a malignant neoplasm code from the C50 category applies. Vague entries like 'breast pain' rarely support an MRI and are common reasons for denial.
Medicare treats breast MRI differently from private plans. Medicare covers diagnostic breast MRI when it is reasonable and necessary, such as for staging a known cancer or resolving an unclear finding, but it generally does not cover MRI as a routine screening benefit. Commercial plans often follow American Cancer Society guidance and cover annual screening MRI for women with a lifetime breast cancer risk of 20 percent or higher, though prior authorization is usually required.
Finally, documentation drives payment. The order should state the indication, laterality, and that contrast is requested, and the report should list the contrast agent, dose, lot number, and any adverse reaction. Retain the risk assessment, such as a Tyrer-Cuzick estimate, when screening is the indication. If an audit arrives, those records prove medical necessity and protect both the imaging center and the patient from retroactive recoupment of payment.
Annual screening MRI is recommended by the American Cancer Society for women with a lifetime breast cancer risk of 20 to 25 percent or more, including BRCA1 and BRCA2 carriers, untested first-degree relatives of carriers, and women who received chest radiation between ages 10 and 30. The study is performed with and without contrast, so 77049 is the standard code for these bilateral exams.
Payers generally expect a documented risk model result or genetic test report attached to the authorization request. Pair 77049 with Z12.39 and the relevant risk diagnosis, and confirm the plan's age limits. Screening is usually timed between days 7 and 14 of the menstrual cycle in premenopausal women, because background parenchymal enhancement is lowest then, which reduces false positives and callbacks.
When a biopsy confirms breast cancer, preoperative MRI can reveal additional foci, chest wall involvement, or disease in the opposite breast. Bilateral staging uses 77049, while a patient with a prior mastectomy on one side uses 77048. Because this is diagnostic rather than screening, the claim carries a malignant neoplasm code from the C50 category, and Medicare typically covers it when medical necessity is documented.
MRI is also used for problem solving after equivocal mammography or ultrasound, evaluation of nipple discharge with negative conventional imaging, and cases of axillary nodal metastasis with an unknown primary. In each case the combined study is preferred, since the contrast-enhancement curve helps separate malignant from benign lesions, and the order should name the specific question the radiologist is expected to answer.
Silicone implant rupture is best evaluated without contrast, using silicone-specific sequences, so 77047 for both breasts or 77046 for one breast is the correct code family. Adding contrast does not improve rupture detection, so a payer may deny 77049 if the only stated indication is implant integrity. Match the code to the actual clinical question and the sequences truly acquired.
For women completing neoadjuvant chemotherapy, MRI measures residual tumor before surgery, and the combined codes apply. Surveillance after breast-conserving therapy may also use 77049 when scarring makes mammography hard to interpret. Document the treatment dates, because many payers limit how soon a follow-up MRI can be repeated, and a study too close to the prior exam without a new symptom is often denied.
If a patient was ordered for 77049 but contrast could not be given because of an infiltrated IV or a last-minute kidney concern, the claim must reflect the study actually performed. That usually means 77047 or 77046. Billing the combined code anyway is a leading cause of overpayment recoupment.
The most frequent mistake is a laterality mismatch. A scheduler selects bilateral, the technologist images one breast because of a prior mastectomy, and the claim still goes out as 77049. Payers compare the report with the claim, and a report describing a single breast will flag the discrepancy. Build a hard stop into your workflow so that the code is finalized only after the radiologist's dictation confirms which breasts were imaged.
A second error is billing the combined code when contrast was never given. Reasons include patient refusal, a failed or infiltrated IV, an acute reaction before injection, or an abnormal kidney function result discovered at the last minute. In every one of these cases, the correct code is the without-contrast version, either 77046 or 77047. Technologists should note the reason contrast was withheld in the exam record so the biller can code accurately.
Some practices still use the legacy Category III code for computer-aided detection, which was deleted when the breast MRI codes were revised in 2023. Reporting it today usually results in an automatic rejection, or worse, a payer interpretation that the practice is double billing the same work. Update charge masters, templates, and superbill forms every January, since outdated codes persist in these documents long after the official manual changes.
MRI-guided breast biopsy is another source of confusion. The biopsy code, 19085 for the first lesion and 19086 for each additional lesion, already includes the imaging guidance, so 77049 should not be added for the same session. Localization procedures use 19281 and 19282 in the same fashion. A separate diagnostic MRI performed on a different day, for a documented reason, can still be billed independently with its own supporting records.
Authorization failures are the most avoidable denials. Many commercial plans require approval before any breast MRI, and the approval is tied to a specific code, facility, and date range. If the exam is performed after the approval window closes, or if the code changes from 77048 to 77049 at the scanner, the authorization may no longer match. Staff should re-verify with the payer whenever the order or schedule changes.
Diagnosis mismatches also cause trouble. A screening diagnosis on a claim the payer considers diagnostic, or the reverse, can send a claim into the wrong benefit category and make the patient responsible for a deductible they did not expect. Medicare patients should be offered an Advance Beneficiary Notice when screening MRI is requested without a covered diagnostic indication, so the financial responsibility is clear before the scan begins.
When a denial does occur, act quickly. Read the explanation of benefits to learn whether the issue was medical necessity, authorization, bundling, or a coding mismatch. Appeals deadlines for commercial plans are commonly 180 days, though some are shorter, so check the contract. A peer-to-peer call between the radiologist or ordering physician and the payer's medical director often resolves necessity denials faster than a written appeal alone.
Out-of-pocket cost for a bilateral breast MRI with and without contrast varies widely. Self-pay prices at freestanding imaging centers often fall between about $1,000 and $2,500, while hospital outpatient departments may charge two to three times that amount for the same study. Those figures reflect typical ranges rather than guarantees, so request a written estimate that lists the CPT code, the contrast charge, and the radiologist fee separately.
Insurance changes the picture considerably. Under most commercial plans, the amount you owe depends on whether you have met your annual deductible, your coinsurance percentage, and whether the facility is in network. A patient with a $2,000 deductible who has not yet paid toward it may owe the full allowed amount, which is usually far below the billed charge, until the deductible is satisfied and coinsurance begins.
Medicare Part B pays 80 percent of the approved amount for covered diagnostic breast MRI after the annual deductible, leaving the patient with 20 percent coinsurance unless supplemental coverage applies. Because routine screening MRI is generally not a covered benefit, a Medicare patient without a diagnostic indication may be asked to sign an ABN and pay privately. Ask the imaging center to explain which category your exam falls into before you schedule.
Prior authorization usually follows a predictable path. The ordering clinician submits the CPT code, diagnosis, and supporting notes, and the payer's utilization management team reviews them, often within two to five business days. Approvals specify the code, facility, and validity window. If the plan requests more information, such as a risk model score or recent mammogram report, supply it promptly, since delays push the exam date and can lapse an existing approval.
Where you scan matters financially. Independent diagnostic testing facilities often negotiate lower rates than hospital departments, and some insurers steer patients toward them with reduced cost sharing. Our guide on where to get an MRI compares facility types, pricing, and accreditation. Look for American College of Radiology accreditation in breast MRI, because it signals that the center meets standards for coils, protocols, and the ability to perform MRI-guided biopsy.
Several states have enacted laws that require coverage for supplemental imaging, including MRI, for patients with dense breast tissue or elevated risk, and these requirements may limit cost sharing. The details differ by state and by whether your plan is fully insured or self-funded. Your employer's benefits office or state insurance department can tell you which rules apply, and that call is worth making before a surprising bill arrives.
If you cannot afford the exam, ask about financial assistance. Nonprofit hospitals are required to maintain charity care policies, and many imaging centers offer prompt-pay discounts of 20 to 40 percent for self-pay patients. Community programs and organizations focused on breast health sometimes fund screening for high-risk women. Always obtain the discounted price in writing and confirm it covers both the facility and radiologist fees before booking the appointment.
For patients, preparation begins with timing. If you have not reached menopause, schedule your breast MRI between days 7 and 14 of your menstrual cycle, when hormonal enhancement of normal tissue is lowest. Bring prior mammograms, ultrasounds, and MRI reports, or have them sent in advance, because the radiologist compares new images with old ones. Comparison studies reduce false alarms and help the radiologist decide whether a finding is stable or new.
Tell the staff about anything implanted or embedded in your body, including pacemakers, tissue expanders with magnetic ports, aneurysm clips, and cochlear implants. Mention kidney disease, prior contrast reactions, pregnancy, and breastfeeding. Most people can receive gadolinium safely, and screening typically involves a short questionnaire and, for some patients, a recent blood test of kidney function. Wear clothing without metal and expect to remove jewelry, hairpins, and underwire garments before changing into a gown.
During the exam, you lie face down with your breasts positioned in a padded, open coil that improves image quality. The table slides into the scanner, and you hear loud knocking sounds, so earplugs or headphones are provided. An IV is placed in your arm, and contrast is injected partway through the exam. Holding still is the most important thing you can do, since motion blurs the post-contrast images that radiologists rely on most.
Technologists should protect image quality by confirming that the coil is properly positioned, the breasts are free of skin folds, and fat suppression or subtraction is working. The first post-contrast acquisition is usually obtained roughly 60 to 120 seconds after injection, with later phases following to build a kinetic curve. Document the injection rate, saline flush, and any extravasation immediately. Accurate technical notes are what let billers choose between the without-contrast and combined codes.
Billers can lower denials by building the order check into scheduling. Require laterality, indication, and authorization status before a slot is confirmed, and reconcile the technologist worksheet with the radiology report before the charge posts. Review denial reports monthly to identify patterns, such as a particular referring office that omits risk documentation. Small front-end fixes like these usually save more revenue than aggressive back-end appeals ever recover.
On safety, macrocyclic gadolinium agents have a very low risk of nephrogenic systemic fibrosis, and many facilities follow ACR guidance to screen only patients with risk factors for reduced kidney function. The FDA has noted that small amounts of gadolinium can be retained in the body, including the brain, although no harm has been established in people with normal kidney function. Patients with concerns should discuss risks, benefits, and alternatives with the ordering clinician.
Students preparing for the ARRT MRI registry should connect coding to protocol. Knowing why a bilateral axial acquisition, fat suppression, and dynamic contrast timing are standard for breast MRI makes the code descriptors easier to remember. Use the practice quizzes below to test contrast safety, coil selection, and sequence knowledge, and review missed questions the same day. Repeating weak topics in short sessions builds retention far better than one long cram session before the exam.
For a fuller set of questions on this topic, see our totally open mri near me resource.
For a fuller set of questions on this topic, see our mri pelvis cpt code resource.
For a fuller set of questions on this topic, see our mri machine images resource.